Alkaline Phosphatase: What This Test Actually Measures

What Alkaline Phosphatase Is (And Why It Is Plural)

Alkaline phosphatase refers to a group of zinc-containing metalloenzymes that catalyze the hydrolysis of phosphate monoesters at a pH above 9. The reaction itself is simple: ALP strips a phosphate group from its substrate and releases inorganic phosphate. But "alkaline phosphatase" on a lab report is actually the sum of activity from multiple tissue-specific forms, each encoded by different genes.

Three genes produce the known human ALP isoenzymes. The tissue-nonspecific ALP gene (ALPL) encodes the liver, bone, and kidney isoforms, which differ only in post-translational glycosylation and sialic acid content [1]. Two separate genes encode the intestinal and placental isoenzymes [2]. Because a standard assay cannot distinguish these forms, total ALP activity can rise for reasons as different as a bile duct stone and a healing fracture.

The clinical value of ALP was first recognized in the 1930s when researchers linked markedly elevated levels to obstructive jaundice and Paget disease of bone [3]. That dual origin still defines the test's main clinical challenge: an isolated ALP elevation on a routine metabolic panel requires additional workup to identify the source organ.

How the Test Works in the Lab

Most clinical laboratories measure ALP using a kinetic rate assay standardized by the International Federation of Clinical Chemistry (IFCC). The sample is mixed with p-nitrophenyl phosphate as substrate at a pH of 10.3 and a temperature of 37 degrees Celsius, and the rate of p-nitrophenol production is measured spectrophotometrically at 405 nm [4]. Results are reported in international units per liter (IU/L), where one unit equals the amount of enzyme that converts one micromole of substrate per minute.

Reference intervals depend on the assay platform, the patient's age, sex, and physiological state. The American Association for Clinical Chemistry (AACC) recognizes this variability and advises labs to establish population-specific reference ranges [5]. A commonly cited adult reference range is 44 to 147 IU/L, though some laboratories use 30 to 120 IU/L for men and 20 to 105 IU/L for non-pregnant women.

When total ALP is elevated, clinicians can order isoenzyme fractionation by heat stability, electrophoresis, or wheat-germ lectin precipitation. Bone ALP is heat-labile and precipitates with lectin, while liver ALP resists heat and remains in the supernatant [6]. A simpler first step is to check gamma-glutamyl transferase (GGT): if GGT is elevated alongside ALP, the source is almost certainly hepatobiliary; if GGT is normal, bone is the likely origin [7].

Normal Alkaline Phosphatase Ranges Across the Lifespan

ALP is one of the most age-dependent analytes in clinical chemistry. Newborns typically show levels of 150 to 420 IU/L, reflecting rapid bone formation [8]. During the pubertal growth spurt, values can reach 500 IU/L or higher. This is not pathological. Pediatric endocrinologists expect ALP to peak at ages 10 to 12 in girls and 12 to 14 in boys, then decline to adult levels by age 17 to 19 [8].

In adults aged 25 to 60, the reference interval narrows considerably. Men typically run slightly higher than premenopausal women. After menopause, bone turnover accelerates, and women's ALP levels may rise 10 to 20 percent above premenopausal baselines, often approaching the male upper limit [9]. The Endocrine Society's 2020 guidelines on postmenopausal osteoporosis list ALP among the bone-turnover markers worth tracking during treatment with antiresorptive agents [10].

Pregnancy is the most dramatic physiological cause of ALP elevation. Placental ALP begins rising in the second trimester and can double or triple total ALP by weeks 36 to 40 [11]. This isoform is heat-stable and can be confirmed on electrophoresis if there is clinical uncertainty. Isolated ALP elevation in a pregnant patient with normal GGT and normal liver enzymes requires no further hepatobiliary workup.

What High Alkaline Phosphatase Means

A total ALP above the upper reference limit warrants interpretation in context, not reflexive alarm. The two broad categories are hepatobiliary and skeletal.

Hepatobiliary causes. ALP is anchored to the canalicular membrane of hepatocytes, and cholestasis (bile flow obstruction) causes its synthesis to increase via bile acid-mediated induction [12]. Common bile duct stones, pancreatic head tumors, primary biliary cholangitis, and drug-induced cholestasis all produce ALP elevations often exceeding three to four times the upper limit. In primary biliary cholangitis, ALP is both a diagnostic criterion and a treatment target: the AASLD's 2018 practice guidance defines biochemical response to ursodeoxycholic acid as ALP <1.67 times the upper limit of normal after 12 months of therapy [13].

"ALP is the single most useful serum marker for biliary obstruction," wrote Dr. Marshall Kaplan in the 2018 edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease. "An ALP elevation exceeding three times the upper limit of normal has a positive predictive value above 90 percent for extrahepatic obstruction when paired with conjugated hyperbilirubinemia" [14].

Skeletal causes. Bone ALP is released by osteoblasts during active bone formation. Paget disease of bone can produce ALP values 10 to 25 times normal, making it the highest non-malignant ALP elevation encountered in clinical practice [15]. Other skeletal causes include healing fractures, osteomalacia, hyperparathyroidism, and osteoblastic bone metastases (commonly from prostate or breast carcinomas).

The Endocrine Society's clinical practice guideline on Paget disease recommends total ALP as the first-line marker for diagnosis and treatment monitoring, noting that bone-specific ALP should be reserved for patients whose total ALP is normal despite active pagetic symptoms [15].

Other causes. Congestive heart failure can raise ALP through hepatic congestion. Chronic kidney disease elevates ALP via renal osteodystrophy. Hyperthyroidism increases bone turnover enough to push ALP above normal in roughly 15 to 20 percent of untreated patients [16].

What Low Alkaline Phosphatase Means

Low ALP gets less attention but carries its own differential. Hypophosphatasia (HPP) is the most specific diagnosis: loss-of-function mutations in the ALPL gene reduce tissue-nonspecific ALP activity, causing accumulation of its natural substrates (inorganic pyrophosphate, pyridoxal 5'-phosphate, and phosphoethanolamine) and defective bone mineralization [17]. The severe perinatal form is rare (approximately 1 in 100,000 births), but mild adult-onset HPP may be underdiagnosed, with carrier frequencies as high as 1 in 300 in European populations [17].

Other causes of low ALP include zinc deficiency (zinc is a cofactor for the enzyme), magnesium deficiency, hypothyroidism, pernicious anemia, and celiac disease [18]. Cardiac surgery with cardiopulmonary bypass can transiently suppress ALP through hemodilution and hypothermia.

"Persistently low ALP in an adult with unexplained fractures or dental issues should prompt measurement of serum pyridoxal 5'-phosphate and urine phosphoethanolamine to rule out hypophosphatasia," according to the AACE's 2020 clinical practice guidelines on metabolic bone disease [19].

How to Lower Alkaline Phosphatase

Because ALP is a marker, not a disease, lowering it means treating the condition driving the elevation. There is no pill that selectively reduces ALP, and chasing the number without a diagnosis is poor medicine.

For biliary obstruction, the treatment is removing the obstruction. Endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction typically normalizes ALP within two to four weeks [20]. For primary biliary cholangitis, ursodeoxycholic acid at 13 to 15 mg/kg/day remains first-line therapy and reduces ALP by a median of 40 to 50 percent within 6 to 12 months [13].

For Paget disease, bisphosphonates are the standard treatment. A single intravenous dose of zoledronic acid 5 mg normalized ALP in 89 percent of patients at six months in the HORIZON trial (N=357), compared to 58 percent with risedronate 30 mg daily for two months [21]. ALP is the primary efficacy endpoint in Paget trials and should be checked at three and six months after treatment.

For vitamin D deficiency causing osteomalacia and elevated bone ALP, repletion with cholecalciferol 50 to 000 IU weekly for 8 to 12 weeks followed by 1,000 to 2 to 000 IU daily is the Endocrine Society's recommended protocol [22]. ALP typically trends down as bone mineralization normalizes, a process that can take three to six months.

Lifestyle factors that can modestly influence ALP include maintaining adequate zinc intake (11 mg/day for men, 8 mg/day for women per the NIH Office of Dietary Supplements) and avoiding excessive alcohol, which can raise GGT and ALP through hepatic inflammation [23].

How to Raise Alkaline Phosphatase

Low ALP rarely requires treatment unless hypophosphatasia is the cause. For adult-onset HPP with recurrent fractures, asfotase alfa (Strensiq) is an enzyme replacement therapy approved by the FDA in 2015 for perinatal, infantile, and juvenile-onset HPP [24]. Use in adults remains off-label but is supported by case series showing improved pain scores, fracture healing, and normalization of pyridoxal 5'-phosphate levels [25].

For nutritional deficiencies causing low ALP, repleting the missing cofactor is sufficient. Zinc supplementation at 15 to 30 mg elemental zinc daily for 8 to 12 weeks can restore ALP in documented zinc deficiency [18]. Correcting hypothyroidism with levothyroxine normalizes bone turnover markers including ALP within three to six months of achieving euthyroidism [16].

Bone ALP vs. Total ALP: When to Order Isoenzymes

Most clinicians rely on the GGT trick: elevated ALP plus elevated GGT points to liver; elevated ALP plus normal GGT points to bone. This heuristic works in about 90 percent of cases [7]. But certain situations call for direct isoenzyme measurement.

Bone-specific ALP (BAP), measured by immunoassay, has a reference range of approximately 6.5 to 22.4 mcg/L in premenopausal women and 5.2 to 24.4 mcg/L in postmenopausal women [26]. The International Osteoporosis Foundation (IOF) and IFCC's Bone Marker Standards Working Group recommend BAP alongside procollagen type I N-propeptide (P1NP) and C-terminal telopeptide (CTX) as the reference bone-turnover markers for clinical trials [27].

Order isoenzyme fractionation or BAP when:

• Total ALP is mildly elevated (1 to 1.5 times the upper limit) and GGT is borderline or unavailable.
• The patient has concurrent liver and bone disease (e.g., alcoholic liver disease with osteoporosis).
• You are monitoring treatment response in Paget disease or osteoporosis and need a bone-specific marker that is not affected by hepatic status.
• A postmenopausal woman on antiresorptive therapy has a rising total ALP, and you need to determine whether the change is skeletal or hepatic.

Drugs That Affect Alkaline Phosphatase Levels

Several medications can raise or lower ALP independent of disease. Anticonvulsants (phenytoin, carbamazepine, phenobarbital) induce hepatic ALP synthesis through the pregnane X receptor and can raise levels 1.5 to 2 times normal [28]. Antibiotics, particularly penicillins and cephalosporins, occasionally cause drug-induced cholestasis with ALP elevations exceeding five times normal [29].

Bisphosphonates lower bone ALP as their intended pharmacologic effect. Denosumab, a RANKL inhibitor, suppresses bone ALP rapidly, often within the first three months of treatment [30]. Oral contraceptives and estrogen replacement therapy may lower ALP by 10 to 15 percent through suppression of bone turnover in premenopausal and postmenopausal women, respectively [9].

Reviewing a patient's medication list is a required step before pursuing expensive or invasive workup for an isolated ALP abnormality.

When ALP Should Trigger Further Testing

An isolated ALP elevation on a routine comprehensive metabolic panel (CMP) does not always need imaging. The American College of Gastroenterology's clinical guideline on evaluation of abnormal liver chemistries recommends the following stepwise approach [31]:

1. Confirm the elevation is persistent by repeating the test in 1 to 4 weeks. Transient elevations are common after fatty meals (intestinal ALP) and minor illness.
2. Check GGT or 5'-nucleotidase. If elevated, the source is hepatobiliary.
3. If hepatobiliary, order a right upper quadrant ultrasound to evaluate for biliary dilation, gallstones, or hepatic mass lesions.
4. If GGT is normal and skeletal disease is suspected, check calcium, phosphate, PTH, 25-hydroxyvitamin D, and bone-specific ALP or P1NP.
5. For persistent unexplained elevations exceeding 1.5 times the upper limit with normal imaging, consider magnetic resonance cholangiopancreatography (MRCP) or liver biopsy to evaluate for infiltrative disease, primary sclerosing cholangitis, or intrahepatic cholestasis.

A single ALP of 160 IU/L in an otherwise healthy 35-year-old with normal GGT, normal bilirubin, and no symptoms can be monitored with a repeat test in three months rather than launching a full imaging workup.